首页> 外文OA文献 >Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors

【2h】

Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors

机译：I级研究针对1型胰岛素样生长因子受体（IGF-1R）的人源化单克隆抗体AVE1642与抗癌疗法组合给予晚期实体肿瘤的患者

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
V.M. Macaulay; M.R. Middleton; A.S. Protheroe; A. Tolcher; V. Dieras; C. Sessa; R. Bahleda; J.-Y. Blay; P. LoRusso; D. Mery-Mignard; J.-C. Soria;
展开▼
作者单位

展开▼
年度 2013
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors [J] . MacaulayV.M., MiddletonM.R., ProtheroeA.S., Annals of oncology: official journal of the European Society for Medical Oncology . 2013,第3期

机译：针对1型胰岛素样生长因子受体（IGF-1R）的人源化单克隆抗体AVE1642的I期研究，与抗癌疗法联合用于晚期实体瘤患者
2. A dose finding, safety and pharmacokinetic study of AVE1642, an anti-insulin-like growth factor-1 receptor (IGF-1R/CD221) monoclonal antibody, administered as a single agent and in combination with docetaxel in patients with advanced solid tumours [J] . SoriaJ.C., MassardC., LazarV., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2013,第8期

机译：一种抗胰岛素样生长因子-1受体（IGF-1R / CD221）单克隆抗体AVE1642的剂量发现，安全性和药代动力学研究，以单药形式与多西他赛联用用于晚期实体瘤患者
3. Phase I Study of the Humanized Antiepidermal Growth Factor Receptor Monoclonal Antibody EMD72000 in Patients With Advanced Solid Tumors That Express the Epidermal Growth Factor Receptor. [J] . Vanhoefer U, Rojo F, Schleucher N, Journal of Clinical Oncology . 2004,第1期

机译：人源化抗表皮生长因子受体单克隆抗体EMD72000在患有表皮生长因子受体的晚期实体瘤患者中的研究。
4. HER1 THERAPEUTIC CANCER VACCINE: AN ACTIVE IMMUNOTHERAPY TREATMENT FOR PATIENTS WITH TUMORS EXPRESSING THE RECEPTOR OF EPIDERMAL GROWTH FACTOR (EGF-R) [C] . Eduardo Suarez, Belinda Sanchez, Zaima Mazorra, Conference on vaccine technology VI . 2018

机译：HER1癌症治疗疫苗：一种针对表皮生长因子（EGF-R）受体的肿瘤的主动免疫疗法
5. Cloning and expression of a biosimilar chimeric monoclonal antibody directed against the human epidermal growth factor receptor and its production in CHO cells for treatment of colo-rectal cancer. [D] . Motiwala, Hatim Maqbulhusen. 2012

机译：针对人表皮生长因子受体的生物仿制药嵌合单克隆抗体的克隆和表达及其在CHO细胞中的产生，用于治疗结肠直肠癌。
6. Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R) administered in combination with anticancer therapies to patients with advanced solid tumors [O] . V. M. Macaulay, M. R. Middleton, A. S. Protheroe, -1

机译：针对1型胰岛素样生长因子受体（IGF-1R）的人源化单克隆抗体AVE1642的I期研究与抗癌药物联合用于晚期实体瘤患者
7. Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma [O] . P Moreau, F Cavallo, X Leleu, 2011

机译：I阶段I研究抗胰岛素样生长因子1受体（IGF-1R）单克隆抗体，AVE1642，作为单一剂，并与多发性骨髓瘤复发患者中的硼替佐米组合

Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors

著录项

引文网络

相似文献

相关主题

期刊订阅